These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21486535)

  • 1. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
    Pichereau S; Le Louarn A; Lecomte T; Blasco H; Le Guellec C; Bourgoin H
    J Pharm Pharm Sci; 2010; 13(4):615-25. PubMed ID: 21486535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
    Wei X; Cai J; Sun H; Li N; Xu C; Zhang G; Sui Y; Zhuang J; Zheng B
    Pharmacogenomics; 2019 Mar; 20(4):241-249. PubMed ID: 30628534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Hazama S; Mishima H; Tsunedomi R; Okuyama Y; Kato T; Takahashi K; Nozawa H; Ando H; Kobayashi M; Takemoto H; Nagata N; Kanekiyo S; Inoue Y; Hamamoto Y; Fujita Y; Hinoda Y; Okayama N; Oba K; Sakamoto J; Oka M
    Cancer Sci; 2013 Dec; 104(12):1662-9. PubMed ID: 24033692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
    Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
    Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
    Butzke B; Oduncu FS; Severin F; Pfeufer A; Heinemann V; Giessen-Jung C; Stollenwerk B; Rogowski WH
    Acta Oncol; 2016; 55(3):318-28. PubMed ID: 26098842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
    Gold HT; Hall MJ; Blinder V; Schackman BR
    Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    Xu JM; Wang Y; Ge FJ; Lin L; Liu ZY; Sharma MR
    World J Gastroenterol; 2013 Jun; 19(24):3899-903. PubMed ID: 23840132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
    Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
    Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Suenaga M; Fuse N; Yamaguchi T; Yamanaka Y; Motomura S; Matsumoto H; Hamamoto Y; Mizunuma N; Doi T; Hatake K; Iwasaki J; Ohtsu A
    J Clin Pharmacol; 2014 May; 54(5):495-502. PubMed ID: 24382596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
    Iwasa S; Muro K; Morita S; Park YS; Nakamura M; Kotaka M; Nishina T; Matsuoka H; Ahn JB; Lee KW; Hong YS; Han SW; Cho SH; Zhang DS; Fang WJ; Bai L; Yuan XL; Yuan Y; Yamada Y; Sakamoto J; Kim TW
    Cancer Sci; 2021 Nov; 112(11):4669-4678. PubMed ID: 34327766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
    Tsai HL; Chen PJ; Chen YC; Li CC; Chang TK; Su WC; Yin TC; Huang CW; Wang JY
    J Int Med Res; 2022 Jul; 50(7):3000605221110697. PubMed ID: 35822291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
    Miyata Y; Touyama T; Kusumi T; Morita Y; Mizunuma N; Taniguchi F; Manabe M
    Int J Clin Oncol; 2016 Aug; 21(4):696-703. PubMed ID: 26710796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
    Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H
    Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.